Hester Biosciences Limited

HESTERBIO

INE782E01017

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 03:34:21 2024-05-17 am EDT			5-day change	1st Jan Change
1,785 ^INR	-0.18%		+2.68%	+22.31%

May. 10	Transcript : Hester Biosciences Limited, Q4 2024 Earnings Call, May 10, 2024
May. 10	Hester Biosciences' Consolidated Net Profit Rises in Fiscal Q4; Shares Jump 4%	MT

Hester Biosciences Ltd Announces Board Changes

October 28, 2013 at 05:08 am EDT

Hester Biosciences Ltd. at the Board of Directors meeting held on October 28, 2013, approved resignation of Mr. Abhinava Shukla as Independent Non Executive Director and appointment of Dr. Siba Kumar Samal as Independent Non Executive Director of the company.

Latest news about Hester Biosciences Limited

Transcript : Hester Biosciences Limited, Q4 2024 Earnings Call, May 10, 2024	May. 10
Hester Biosciences' Consolidated Net Profit Rises in Fiscal Q4; Shares Jump 4%	May. 10	MT
Hester Biosciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 10	CI
Hester Biosciences Limited Proposes Dividend for the Financial Year 2023- 24	May. 10	CI
Hester Biosciences Names COO	Feb. 29	MT
Hester Biosciences Limited Announces Executive Changes	Feb. 29	CI
Hester Biosciences Sees Sharp Decline in Fiscal Q3 Consolidated Profit	Feb. 02	MT
Transcript : Hester Biosciences Limited, Q3 2024 Earnings Call, Feb 02, 2024	Feb. 02
Hester Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 02	CI
CARE Ratings Keeps BBB+ Rating on Hester Biosciences' Bank Financing; Outlook Stable	Jan. 03	MT
Transcript : Hester Biosciences Limited, Q2 2024 Earnings Call, Nov 07, 2023	Nov. 07
Hester Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 07	CI
Hester Biosciences Limited Recommends Dividend for the Financial Year 2022-23, Dividend Payment Date on or After Monday, 25 September 2023	23-08-23	CI
Transcript : Hester Biosciences Limited, Q1 2024 Earnings Call, Aug 08, 2023	23-08-08
Hester Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-08	CI
Hester Biosciences Limited Announces Board Appointments	23-06-27	CI
Transcript : Hester Biosciences Limited, Q4 2023 Earnings Call, May 17, 2023	23-05-17
Hester Biosciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-17	CI
Hester Biosciences Limited Recommends Dividend for the Financial Year 2022-23	23-05-17	CI
Hester Biosciences Limited Announces Resignation of Directors	23-03-27	CI
Hester Biosciences Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	23-01-31	CI
Transcript : Hester Biosciences Limited, Q3 2023 Earnings Call, Jan 31, 2023	23-01-31
Hester Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-01-31	CI
Hester Biosciences Limited completed the acquisition of 22.5% stake in Thrishool Exim Limited.	22-12-30	CI
Hester Biosciences Acquires Indigenous Technology for Avian Influenza Vaccine	22-12-28	MT

Chart Hester Biosciences Limited

Duration

Period

More charts

Company Profile

Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
HESTER BIOSCIENCES LIMITED	+22.31%	182M
ZOETIS INC.	-11.98%	79.26B
BLUESTAR ADISSEO COMPANY	+25.75%	3.74B
VIRBAC	-0.56%	3.27B
VIMIAN GROUP AB	+17.06%	1.69B
JINYU BIO-TECHNOLOGY CO., LTD.	-6.22%	1.56B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-23.36%	1.29B
VETOQUINOL SA	-1.76%	1.28B
WUHAN KEQIAN BIOLOGY CO.,LTD	-12.76%	1.14B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	+0.79%	1.06B

Veterinary Drugs

Hester Biosciences Limited

Equities

HESTERBIO

INE782E01017

Pharmaceuticals

Hester Biosciences Ltd Announces Board Changes

Latest news about Hester Biosciences Limited

Chart Hester Biosciences Limited

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Veterinary Drugs